230 related articles for article (PubMed ID: 10063942)
1. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
Castaño G; Más R; Roca J; Fernández L; Illnait J; Fernández JC; Selman E
Angiology; 1999 Feb; 50(2):123-30. PubMed ID: 10063942
[TBL] [Abstract][Full Text] [Related]
2. A long-term study of policosanol in the treatment of intermittent claudication.
Castaño G; Más Ferreiro R; Fernández L; Gámez R; Illnait J; Fernández C
Angiology; 2001 Feb; 52(2):115-25. PubMed ID: 11228084
[TBL] [Abstract][Full Text] [Related]
3. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study.
Castaño G; Más R; Fernández L; Gámez R; Illnait J
Angiology; 2003 Jan; 54(1):25-38. PubMed ID: 12593493
[TBL] [Abstract][Full Text] [Related]
4. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study.
Castaño G; Más R; Gámez R; Fernández L; Illnait J
Angiology; 2004; 55(4):361-71. PubMed ID: 15258682
[TBL] [Abstract][Full Text] [Related]
5. Effects of policosanol (10 mg/d) versus aspirin (100 mg/d) in patients with intermittent claudication: a 10-week, randomized, comparative study.
Illnait J; Castaño G; Alvarez E; Fernández L; Mas R; Mendoza S; Gamez R
Angiology; 2008; 59(3):269-77. PubMed ID: 18388038
[TBL] [Abstract][Full Text] [Related]
6. Concomitant use of policosanol and beta-blockers in older patients.
Castaño G; Mas R; Gámez R; Fernández J; Illnait J; Fernández L; Mendoza S; Mesa M; Gutiérrez JA; López E
Int J Clin Pharmacol Res; 2004; 24(2-3):65-77. PubMed ID: 15689053
[TBL] [Abstract][Full Text] [Related]
7. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients.
Arruzazabala ML; Más R; Molina V; Carbajal D; Mendoza S; Fernández L; Valdés S
Int J Tissue React; 1998; 20(4):119-24. PubMed ID: 10093795
[TBL] [Abstract][Full Text] [Related]
8. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
[TBL] [Abstract][Full Text] [Related]
9. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
Castaño G; Fernández L; Mas R; Illnait J; Gámez R; Mendoza S; Mesa M; Fernández J
Drugs R D; 2005; 6(4):207-19. PubMed ID: 16050054
[TBL] [Abstract][Full Text] [Related]
10. A pharmacological surveillance study of the tolerability of policosanol in the elderly population.
Fernández S; Más R; Gamez R; Diaz A; Fernández J; Deibis Orta S; Illnait J; Castańo G; Mendoza S; Valdés F; Alvarez E
Am J Geriatr Pharmacother; 2004 Dec; 2(4):219-29. PubMed ID: 15903280
[TBL] [Abstract][Full Text] [Related]
11. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up.
Delis KT; Nicolaides AN; Wolfe JH; Stansby G
J Vasc Surg; 2000 Apr; 31(4):650-61. PubMed ID: 10753272
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women.
Mirkin A; Mas R; Martinto M; Boccanera R; Robertis A; Poudes R; Fuster A; Lastreto E; Yañez M; Irico G; McCook B; Farré A
Int J Clin Pharmacol Res; 2001; 21(1):31-41. PubMed ID: 11708573
[TBL] [Abstract][Full Text] [Related]
13. Monograph. Policosanol.
Altern Med Rev; 2004 Sep; 9(3):312-7. PubMed ID: 15387722
[No Abstract] [Full Text] [Related]
14. A comparison of the effects of D-003 and policosanol (5 and 10 mg/day) in patients with type II hypercholesterolemia: a randomized, double-blinded study.
Castaño G; Más R; Fernández L; Illnait J; Mendoza S; Gámez R; Fernández J; Mesa M
Drugs Exp Clin Res; 2005; 31 Suppl():31-44. PubMed ID: 16444910
[TBL] [Abstract][Full Text] [Related]
15. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial.
Berthold HK; Unverdorben S; Degenhardt R; Bulitta M; Gouni-Berthold I
JAMA; 2006 May; 295(19):2262-9. PubMed ID: 16705107
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus.
Crespo N; Illnait J; Más R; Fernández L; Fernández J; Castaño G
Int J Clin Pharmacol Res; 1999; 19(4):117-27. PubMed ID: 10939029
[TBL] [Abstract][Full Text] [Related]
17. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients.
Castaño G; Más R; Arruzazabala ML; Noa M; Illnait J; Fernández JC; Molina V; Menéndez A
Int J Clin Pharmacol Res; 1999; 19(4):105-16. PubMed ID: 10939028
[TBL] [Abstract][Full Text] [Related]
18. Long-term therapy with policosanol improves treadmill exercise-ECG testing performance of coronary heart disease patients.
Stüsser R; Batista J; Padrón R; Sosa F; Pereztol O
Int J Clin Pharmacol Ther; 1998 Sep; 36(9):469-73. PubMed ID: 9760006
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia.
Alcocer L; Fernández L; Campos E; Más R
Int J Tissue React; 1999; 21(3):85-92. PubMed ID: 10645516
[TBL] [Abstract][Full Text] [Related]
20. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
